Aflac’s third quarter performance was met with a positive market reaction, as results surpassed Wall Street’s revenue and non-GAAP profit expectations. Management attributed the quarter’s solid showing to ongoing strength in both the Japan and U.S. segments. In Japan, growth was supported by persistent demand for cancer and medical insurance, while the U.S. business saw momentum in its group life, disability, and network dental products. CEO Dan Amos highlighted that “Aflac U.S. generated a year-over-year 3.5% increase in sales for the third quarter,” driven by strategic expansion of its distribution channels and new product initiatives.

Is now the time to buy AFL? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our top 5 analyst questions from Aflac’s Q3 earnings call

• Wilma Burdis (Raymond James & Associates) asked about the runway for further Bermuda reinsurance transactions. CFO Max Brodén clarified that Aflac Japan has significant headroom, with an internal target of up to 30% of reserves ceded.
• Wilma Burdis (Raymond James & Associates) also questioned capital deployment priorities. Brodén responded that organic policy growth in the U.S. and Japan remains the highest return use of capital, with third-party reinsurance providing selective opportunity.
• Tom Gallagher (Evercore ISI) inquired about behavioral health claim pressures in U.S. group disability. President Virgil Miller noted that Aflac’s exposure is minimal, and the segment remains an area of disciplined growth.
• Tom Gallagher (Evercore ISI) asked about asset-intensive product growth in Japan. Brodén and CEO Dan Amos explained that while first sector growth is attractive in the current rate environment, the company remains cautious to balance risk and capital requirements.
• Tracy Benguigui (Wolfe Research) probed the pace of future reinsurance cessions and impact of switch trades. Brodén said future transactions may not follow a linear path, while CIO Brad Dyslin emphasized that further switch trades will depend on market yield and capital impacts.

Catalysts in upcoming quarters

In the coming quarters, key factors to watch include (1) the pace of additional reinsurance transactions between Aflac Japan and Bermuda, (2) sustained growth in U.S. group and network dental products, and (3) the ongoing impact of product mix shifts, particularly Tsumitasu’s contribution in Japan. Continued capital deployment and responses to macroeconomic changes will also be key indicators of execution.

Aflac currently trades at $129.32, up from $125.30 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

The best stocks for high-quality investors

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.